REPLIGEN CORP Foreign Income Tax Expense (Benefit), Continuing Operations
REPLIGEN CORP (RGEN) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $15.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-26
- REPLIGEN CORP foreign income tax expense (benefit), continuing operations for fiscal 2025 was $15.34M, a 7.85% increase from fiscal 2024.
- REPLIGEN CORP foreign income tax expense (benefit), continuing operations for fiscal 2024 was $14.22M, a 24.61% decline from fiscal 2023.
- REPLIGEN CORP foreign income tax expense (benefit), continuing operations for fiscal 2023 was $18.86M, a 33.43% increase from fiscal 2022.
- REPLIGEN CORP foreign income tax expense (benefit), continuing operations for fiscal 2022 was $14.14M, a 9.83% decline from fiscal 2021.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 9 month | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $15.34M 10-K · filed 2026-02-26 | ||
| 2024-12-31 | $14.22M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $18.86M 10-K · filed 2026-02-26 | $18.90M 10-K · filed 2024-02-22 | |
| 2022-12-31 | $14.14M 10-K · filed 2025-03-14 | ||
| 2021-12-31 | $15.68M 10-K/A · filed 2024-11-18 | ||
| 2020-12-31 | $7.04M 10-K · filed 2023-02-22 | ||
| 2019-12-31 | $7.47M 10-K · filed 2022-02-17 | ||
| 2018-12-31 | $4.49M 10-K · filed 2021-02-24 | ||
| 2017-12-31 | $3.35M 10-K · filed 2020-02-26 | ||
| 2016-12-31 | $4.03M 10-K · filed 2019-03-01 | ||
| 2015-12-31 | $3.51M 10-K · filed 2018-02-22 | ||
| 2014-12-31 | $2.82M 10-K · filed 2017-02-23 | $2.82M 10-K · filed 2015-03-17 | |
| 2013-12-31 | $2.29M 10-K · filed 2016-02-25 | $2.29M 10-K · filed 2014-03-14 | |
| 2012-12-31 | -$84.27K 10-K · filed 2015-03-17 | ||
| 2011-12-31 | -$32.26K 10-K · filed 2014-03-14 | -$32.23K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |